ALK+ lung cancer patients use the new drug erlotinib much better than the “old drug†crizotinib, with no progression survival of 25.7 months vs 10.4 months, prolonged by 15.3 months. Capitalized clothes! After the diagnosis of lung cancer, luck is very important. If you can have targeted medicine, it is very "lucky". Compared with the toxic drugs with relatively high toxicity, many targeted drugs have good effects, and the side effects are small. It is good to eat a few pills every day, just like normal people, it is quite good. If the patient has EGFR mutations, you can use Iressa / Tarceva and 9291 and other targeted drugs, the effect is very good. If there are genetic problems such as C-Met, ROS-1, RET, etc., there are also good targeted drugs, such as crizotinib and E7080. In addition, there are a small number of patients (5% of lung adenocarcinoma) are more fortunate, they have ALK gene fusion, can eat better targeted drugs, high efficiency (more than 70%), side effects are not big, one If you don't pay attention to the tumor, you will give it "eat no more." According to the previous treatment guidelines: For patients who have just been diagnosed with ALK fusion, the first drug to be used should be crizotinib, which is already available in the country and can be purchased by the hospital under the trade name Secari. However, according to the latest clinical data, these newly diagnosed ALK-fused lung cancer patients have a new choice for first-line medications - Alectinib. Today, the authoritative medical journal New England Journal of Medicine has published a large clinical data: for newly diagnosed ALK-fused lung cancer patients, the use of erlotinib is more efficient and has fewer side effects than crizotinib. This phase III clinical trial code, ALEX, is a global multicenter clinical trial. Clinical design A total of 303 newly diagnosed patients with ALK-positive non-small lung cancer were enrolled: 152 were treated with erlotinib orally 600 mg twice daily; 151 were treated with crizotinib orally 250 mg twice daily. Efficient Overall, the effective rate of the erlotinib group was 82.9%, including 4% of patients with complete tumor disappearance; the effective rate of the crizotinib group was 75.5%, and 1% of patients had complete tumor disappearance. If only patients with clear brain lesions were seen, the effective rate of erlotinib was 81% (17 of 21 patients were effective), and the effective rate of the crizotinib group was only 50% (11 of 22 patients were effective) . The final score of 2:0, Electini wins, especially for patients with brain metastases. The specific data is as follows: Progression free survival The independent review committee assessed the progression-free survival of the erlotinib group was 25.7 months, and the crizotinib group was only 10.4 months. Electinib increased by 15.3 months and completely broke the crizotinib. The specific data is as follows: Brain control After one year of treatment, the brain progression rate was only 9.4% in the erlotinib group and 41.4% in the crizotinib group. Electini has won again. Brain metastasis is a bruise on the old drug crizotinib. All ALK-positive patients who are currently taking crizotinib must pay attention to timely detection of the brain. The specific data is as follows: Urine bag,pee bag,urine collection bag,urine leg bag 2 MEDS TECHONOLOGY CO.,LTD , https://www.2-meds.com
